Regeneron Pharmaceuticals, Inc. revealed that the European Medicines Agency is reviewing their Marketing Authorization Application for the therapy, linvoseltamab.

Methylphenidate hydrochloride is a leading CNS stimulant, first approved by the US on December 5, 1955, and developed by Novartis. It effectively treats narcolepsy, ADD, and ADHD.

4DMT Unveils Encouraging Early Results of the Phase 2 PRISM Study for the Eye Injection 4D-150, Indicating Good Safety and Efficacy in Treating Wet Age-Related Macular Degeneration.

Carvedilol, sold under the trade name Coreg, is a medication that was first approved in Belgium in 1990.

Inmagene Biopharmaceuticals has announced its intention to acquire a solo, global license with royalties for IMG-007, a non-eliminating humanized antibody targeting OX40, and IMG-004, a systemically administered BTK inhibitor with non-covalent, reversible mechanisms.

Lamotrigine, approved by the US FDA on Dec 27, 1994, is a leading anticonvulsant drug developed by GlaxoSmithKline.

European Medicines Agency Approves Review of Tisotumab Vedotin Filing for Relapsed or Spreading Cervical Cancer Therapy.

Magnesium citrate is a type of small molecule drug that is a combination of magnesium and citric acid in a 1:1 ratio.

Ascendis Pharma unveils its second TransCon™ offering: YORVIPATH® hits markets in Germany and Austria, targeting chronic hypoparathyroidism in adults.

Cefdinir, marketed under the brand name Omnicef, is a small molecule drug that acts as a penicillin-binding protein (PBP) inhibitor and a cell wall inhibitor.

NeuroBo Pharmaceuticals has received approval from the FDA for a Phase 1 clinical study of DA-1726, a new drug aimed at managing obesity.

Fluconazole is a small molecule drug used to treat various fungal infections. It is sold under the trade names Diflucan, Zoltec, and Loitin.